Clinical Trial Update: A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study) [Phase 2]

View source ↗

Summary

A Phase IIa trial of subcutaneous AER 001 in atopic asthmatics with antigen challenge has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Asthma

Drugs mentioned

• AER 001

Snippet

Sponsor: Aerovance, Inc. | Conditions: Allergic Asthma | Phase 2 | Status: COMPLETED